• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CMPX

    Compass Therapeutics Inc.

    Subscribe to $CMPX
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

    IPO Year:

    Exchange: NASDAQ

    Website: compasstherapeutics.com

    Peers

    $CODI
    $CMPS
    $SGTX

    Recent Analyst Ratings for Compass Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    4/2/2025$6.00Market Perform → Outperform
    Leerink Partners
    2/24/2025$12.00Buy
    Guggenheim
    2/19/2025$12.00Overweight
    Piper Sandler
    12/23/2024$32.00Buy
    D. Boral Capital
    11/15/2024$5.00 → $4.00Outperform → Market Perform
    Leerink Partners
    9/16/2024$5.00Neutral → Buy
    Ladenburg Thalmann
    1/31/2023$8.00Buy
    Jefferies
    1/27/2023$9.00Buy
    Stifel
    5/23/2022$12.00Buy
    H.C. Wainwright
    3/15/2022$7.00Buy
    Ladenburg Thalmann
    See more ratings

    Compass Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Compass Therapeutics Inc.

      10-Q - Compass Therapeutics, Inc. (0001738021) (Filer)

      5/8/25 8:01:09 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Compass Therapeutics, Inc. (0001738021) (Filer)

      5/8/25 8:00:29 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Compass Therapeutics Inc.

      DEFA14A - Compass Therapeutics, Inc. (0001738021) (Filer)

      4/29/25 1:27:48 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Compass Therapeutics Inc.

      DEF 14A - Compass Therapeutics, Inc. (0001738021) (Filer)

      4/29/25 8:30:15 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Compass Therapeutics Inc.

      SCHEDULE 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      4/11/25 7:21:13 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Compass Therapeutics Inc.

      144 - Compass Therapeutics, Inc. (0001738021) (Subject)

      4/9/25 6:58:43 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Compass Therapeutics Inc.

      144 - Compass Therapeutics, Inc. (0001738021) (Subject)

      4/9/25 6:51:50 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Compass Therapeutics, Inc. (0001738021) (Filer)

      4/1/25 7:00:17 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Compass Therapeutics Inc.

      S-8 - Compass Therapeutics, Inc. (0001738021) (Filer)

      3/27/25 6:39:40 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Compass Therapeutics Inc.

      10-K - Compass Therapeutics, Inc. (0001738021) (Filer)

      2/27/25 8:30:35 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Compass Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:30:55 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:25:57 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Compass Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

      BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa

      12/10/24 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Announces CEO Transition

      BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available

      5/28/24 4:10:20 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

      Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumExpanded the management team with the appointment of Minori Rosales, M.D. PhD, as Senior Vice President & Head of Clinical DevelopmentAppointed Richard Lindahl, M.B.A., EVP & CFO of Emergent BioSolutio

      5/4/23 8:30:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

      JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted Entera's request for a Type C Meeting based on the revised phase 3 registrational study for lead clinical asset, EB613 (oral formulation of PTH (1-34, teriparatide), as the first oral anabolic drug to treat post-menopausal women with osteoporosis. The meeting is expected in H2 2022Following its End of Phase 2 Meeting with the FDA, Entera designed the pivotal study for EB613 as an 18 month double blind placebo-contro

      7/18/22 7:05:00 AM ET
      $CMPX
      $DERM
      $ENTX
      $NXGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy

      BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera's existing board members, as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately. "Miranda is an accomplished leader in the biotechnology industry with almost 25 years of C-level leadership, principal investment and capital markets experience," commented Spiros Jamas, Chief Executive Officer of Entera Bio. "Ms. Toledano, as a member of our Board of Directors since 2018, has an extensive understanding of Entera's

      5/16/22 8:00:00 AM ET
      $CMPX
      $DERM
      $ENTX
      $NXGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • Compass Therapeutics Announces Appointment of Two New Directors to its Board

      BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today is pleased to announce the appointment of two new directors to its board. Joining the board of directors are Ellen Chiniara, JD, former Chief Legal Officer of Alexion Pharmaceuticals, and Mary Ann Gray, PhD, President of Gray Strategic Advisors. Ms. Chiniara and Dr. Gray are both global leaders with deep experience in the life sciences and biopharmaceutical industries. "Ellen and Mary Ann bring immediate and significant value to our board. Ellen's expertis

      4/26/22 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Compass Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gordon Carl L sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/11/25 7:37:43 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Orbimed Advisors Llc sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/11/25 7:24:24 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:30:55 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      4/8/25 9:25:57 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO Shin Barry

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      2/13/25 5:12:31 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CHIEF EXECUTIVE OFFICER Schuetz Thomas J.

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      2/13/25 5:12:03 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Lindahl Richard S

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      2/13/25 5:11:36 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by SVP, CAO Lerner Neil

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      2/13/25 5:11:11 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Gray Mary Ann

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      2/13/25 5:10:43 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Ferneau Philip

      4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

      2/13/25 5:10:18 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Compass Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Compass Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Compass Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

      Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting. First patient dosed and actively enrolling patients in an Investigator Sponsored Trial (IST) evaluating tovecimig in patients with BTC in the first-line setting.Successfully completed a pre-IND meeting for CTX-10726 (PD-1 x VEGF-A bispecific antibody), maintaining progress towards expected Q4 2025 IND filing and 2026 clinical data.Advanced the

      5/8/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics to Participate in Upcoming May Investor Events

      BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences ConferenceLocation: New York, NYDate: Thursday, May 8, 2025 Time: 1:30 PM ETWebcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQLocation: New York, NYDate: Tuesday, May 20, 2025 Time: 11:30AM ETWebcast Link: https://journey.ct.events/view/29729b86-5109-46dc-a93b-1cf3

      5/6/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

      CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors.Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models.Tovecimig in combination with CTX-471 showed evidence of enhanced innate and adaptive anti-tumor immunity ranging from increased tumor cell killing to increased antigen presentation and interferon signaling.The combination of tovecimig and CTX-471 has the potential to be an effective therapeutic regimen in patients where checkpoint inhibitors have failed, including anti-PD-1 and anti-PD-L1 antibodies. BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeu

      4/28/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

      BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center. "This first-line study of tovecimig in patients with BTC represents a significant step forward and we are deeply grateful to the dedicated team at MD Anderson for their lea

      4/21/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

      BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. Presentation Details Date: Tuesday, April 8, 2025 Time: 3:00 PM EDTWebcast Link: https://wsw.com/webcast/stifel99/cmpx/2119000 Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass' Events page. About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmac

      4/2/25 4:05:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

      Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.The study also showed differences between treatment arms for other efficacy measures, including progressive disease (PD) rates of 16.2% in patients on tovecimig in combination with paclitaxel versus 42.1

      4/1/25 7:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

      Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).  Webinar Details: Date: Tuesday, April 1, 2025 Time: 8 AM EDT Webcast: https://viavid.webcasts.co

      3/31/25 4:05:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

      Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025.Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025.Continued to advance CTX-10726 (PD-1 x VEGF-A bispecific antibody) towards expected year-end 2025 IND filing, with clinical data expected in 2026.Planning to initiate two Phase 2 clinical trials in mid-2025 using novel biomarkers: tovecimig [in DLL4-positive colorectal cancer (CRC) in combination w

      2/27/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference

      BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Guggenheim Securities SMID Cap Biotech Conference taking place in New York City, NY February 5-6, 2025. Presentation Details Date: Thursday, February 6, 2025Time: 9:00-9:25 AM ESTWebcast Link: https://wsw.com/webcast/guggen2/cmpx Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass' Events page. About Compass TherapeuticsCompass Therapeutics, Inc. is a clinical-stage

      1/29/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

      Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x VEGF-A bispecific) is advancing as a new drug candidate after a year of preclinical development, with YE 2025 IND expected.Two Phase 2 biomarker trials are expected to initiate in mid-2025: tovecimig (in DLL4-positive colorectal cancer) and CTX-471 (in NCAM/CD56 expressing tumors).Fully enrolled the third dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific) with preliminary data expected in the second half of 2025.Estimated $127 million in cash and marketable secu

      1/8/25 8:00:00 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Compass Therapeutics from Market Perform to Outperform and set a new price target of $6.00

      4/2/25 8:43:28 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Compass Therapeutics with a new price target

      Guggenheim initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $12.00

      2/24/25 7:07:23 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Compass Therapeutics with a new price target

      Piper Sandler initiated coverage of Compass Therapeutics with a rating of Overweight and set a new price target of $12.00

      2/19/25 7:01:43 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • D. Boral Capital initiated coverage on Compass Therapeutics with a new price target

      D. Boral Capital initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $32.00

      12/23/24 7:56:53 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Compass Therapeutics from Outperform to Market Perform and set a new price target of $4.00 from $5.00 previously

      11/15/24 8:33:16 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics upgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann upgraded Compass Therapeutics from Neutral to Buy and set a new price target of $5.00

      9/16/24 7:26:17 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Compass Therapeutics with a new price target

      Jefferies initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $8.00

      1/31/23 7:10:07 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel initiated coverage on Compass Therapeutics with a new price target

      Stifel initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $9.00

      1/27/23 7:11:51 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright resumed coverage on Compass Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Compass Therapeutics with a rating of Buy and set a new price target of $12.00

      5/23/22 7:10:49 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ladenburg Thalmann initiated coverage on Compass Therapeutics with a new price target

      Ladenburg Thalmann initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $7.00

      3/15/22 8:44:41 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

      Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details:   Date:  May 04, 2022   Time: 8:00 a.m. ET   Webcast: Registration Link   Replay availability: A replay will be available on the Compass website for 6 months. Abo

      5/3/22 4:01:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • OTC Markets Group Announces Quarterly Index Performance and Rebalancing

      NEW YORK, July 20, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced the second quarter 2021 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTCQX Canada Index and the OTCQX Dividend Index. The OTCQX Composite Index (.OTCQX), a benchmark for the overall OTCQX Best Market, was up 3.9% in the second quarter. Ninety-two new companies were added to the index, including: AirBoss of America Corp. (OTCQX:ABSSF); Blackrock Silver Corp. (OTCQX:BKRRF); Belo Sun Mining Corp. (OTCQX:BSXGF); Caldwell Partners International Inc. (OTCQX:CWLPF); Graphite One Inc. (OTCQX:GPHOF)

      7/20/21 4:00:00 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Compass Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Compass Therapeutics Inc.

      SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      11/14/24 10:00:35 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Compass Therapeutics Inc.

      SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

      8/2/24 4:15:57 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Compass Therapeutics Inc. (Amendment)

      SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      3/22/24 4:59:51 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Compass Therapeutics Inc. (Amendment)

      SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      2/9/24 8:50:19 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Compass Therapeutics Inc. (Amendment)

      SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      2/7/24 7:05:08 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Compass Therapeutics Inc.

      SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

      2/1/24 10:19:49 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Compass Therapeutics Inc.

      SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

      11/27/23 4:10:14 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Compass Therapeutics Inc. (Amendment)

      SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      2/14/23 2:58:14 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Compass Therapeutics Inc. (Amendment)

      SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      2/13/23 5:20:40 PM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Compass Therapeutics Inc. (Amendment)

      SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

      2/9/23 8:14:52 AM ET
      $CMPX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care